Human medicines European public assessment report (EPAR): Rubraca, rucaparib, Ovarian Neoplasms, Date of authorisation: 23/05/2018, Revision: 15, Status: Authorised

Omega-3-acid ethyl esters : List of nationally authorised medicinal products - PSUSA-00010312-202301

Human medicines European public assessment report (EPAR): Kalydeco, ivacaftor, Cystic Fibrosis, Date of authorisation: 23/07/2012, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR): Inaqovi, cedazuridine,decitabine, Leukemia, Myeloid, Date of authorisation: 15/09/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Arthritis, Rheumatoid;Arthritis, Psoriatic;Psoriasis;Spondylitis, Ankylosing;Uveitis;Hidradenitis Suppurativa;Colitis, Ulcerative;Crohn Disease;Arthritis, Juvenile Rheumatoid, Date of authorisation: 11/02/2021, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Ventavis, iloprost, Hypertension, Pulmonary, Date of authorisation: 15/09/2003, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Soliris, eculizumab, Hemoglobinuria, Paroxysmal, Date of authorisation: 20/06/2007, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR): Thalidomide BMS (previously Thalidomide Celgene), thalidomide, Multiple Myeloma, Date of authorisation: 16/04/2008, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Abevmy, bevacizumab, Colorectal Neoplasms;Breast Neoplasms;Ovarian Neoplasms;Fallopian Tube Neoplasms;Peritoneal Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms, Date of authorisation: 21/04/2021, Revision: 6, Status: Authorised

Antimicrobial resistance in veterinary medicine